DE102022100991A1 - Device for the controlled administration of a blood sugar-lowering agent - Google Patents
Device for the controlled administration of a blood sugar-lowering agent Download PDFInfo
- Publication number
- DE102022100991A1 DE102022100991A1 DE102022100991.2A DE102022100991A DE102022100991A1 DE 102022100991 A1 DE102022100991 A1 DE 102022100991A1 DE 102022100991 A DE102022100991 A DE 102022100991A DE 102022100991 A1 DE102022100991 A1 DE 102022100991A1
- Authority
- DE
- Germany
- Prior art keywords
- sugar
- blood
- lowering
- controlled administration
- blood sugar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008280 blood Substances 0.000 title abstract 2
- 210000004369 blood Anatomy 0.000 title abstract 2
- 239000004480 active ingredient Substances 0.000 claims abstract description 10
- 239000013543 active substance Substances 0.000 claims abstract description 5
- DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical compound CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229950011186 semaglutide Drugs 0.000 claims abstract description 4
- 108010060325 semaglutide Proteins 0.000 claims abstract description 4
- 230000008591 skin barrier function Effects 0.000 claims abstract description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 4
- 239000000853 adhesive Substances 0.000 claims abstract description 3
- 230000001070 adhesive effect Effects 0.000 claims abstract description 3
- 239000011159 matrix material Substances 0.000 claims abstract description 3
- 239000012528 membrane Substances 0.000 claims abstract description 3
- 239000008177 pharmaceutical agent Substances 0.000 claims abstract description 3
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 229940126904 hypoglycaemic agent Drugs 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 abstract description 4
- 239000013585 weight reducing agent Substances 0.000 abstract description 2
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- 230000003178 anti-diabetic effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 description 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 1
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 description 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 1
- 239000000859 incretin Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Die vorliegende Erfindung betrifft eine Einrichtung zur kontrollierten Verabreichung eines blutzuckersenkenden Wirkstoffes, insbesondere für die Behandlung eines Typ-2-Diabetes und zur Gewichtsreduktion. Die erfindungsgemäße Einrichtung ist dadurch gekennzeichnet, dass sie ein flexibles, klebendes, pharmazeutisches Mittel zum Auflegen auf die Haut umfasst, das einen oder mehrere blutzuckersenkende Wirkstoffe enthält, wobei die Einrichtung ausgebildet ist, den enthaltenen Wirkstoff in kontinuierlicher Weise über die Hautbarriere in den Blutkreislauf abzugeben. Das Mittel ist in einer vorteilhaften Ausführungsform der Erfindung ein Matrix- oder Membranpflaster, wobei der blutzuckersenkende Wirkstoff vorzugsweise Semaglutid ist.The present invention relates to a device for the controlled administration of an active substance that lowers blood sugar, in particular for the treatment of type 2 diabetes and for weight reduction. The device according to the invention is characterized in that it comprises a flexible, adhesive, pharmaceutical agent for application to the skin, which contains one or more blood-sugar-lowering active ingredients, the device being designed to deliver the active ingredient contained in a continuous manner across the skin barrier into the bloodstream. In an advantageous embodiment of the invention, the agent is a matrix or membrane patch, the blood-sugar-lowering active substance preferably being semaglutide.
Description
Technisches Gebiettechnical field
Die vorliegende Erfindung betrifft eine Einrichtung zur kontrollierten Verabreichung eines blutzuckersenkenden Wirkstoffes gemäß dem Oberbegriff des Patentanspruchs 1.The present invention relates to a device for the controlled administration of a blood-sugar-lowering agent according to the preamble of patent claim 1.
Stand der TechnikState of the art
Aus dem Stand der Technik ist es bekannt, für die Behandlung eines Typ-2-Diabetes und zur Gewichtsreduktion einen blutzuckersenkenden Wirkstoff anzuwenden. Neben den zahlreichen oral einzunehmenden Mitteln werden auch Wirkstoffe eingesetzt, die in den Körper in definierten Abständen injiziert werden. Hier kommt bspw. der Wirkstoff Semaglutid zum Einsatz. Semaglutid hat blutzuckersenkende und antidiabetische Eigenschaften, die auf der Bindung an den GLP-1-Rezeptor, einem GPCR (G protein-coupled receptor) beruhen, wobei dieser Rezeptor auch vom Inkretin GLP-1 aktiviert wird.It is known from the prior art to use a blood-sugar-lowering agent for the treatment of type 2 diabetes and for weight reduction. In addition to the numerous drugs to be taken orally, active ingredients are also used that are injected into the body at defined intervals. Here, for example, the active ingredient Semaglutid is used. Semaglutide has hypoglycemic and antidiabetic properties based on binding to the GLP-1 receptor, a GPCR (G protein-coupled receptor), which receptor is also activated by the incretin GLP-1.
Der Nachteil einer Injezierung eines solchen Wirkstoffes ist insbesondere darin zu sehen, dass diese Form der Verabreichung einerseits unangenehm ist, die Kontrolle einer kontinuierlichen Einnahme des Medikaments nicht sicherstellt ist und das Medikament von Patienten aufgrund der Behandlungsweise nach einiger Zeit teils wieder abgesetzt wird.The disadvantage of injecting such an active ingredient can be seen in particular in the fact that this form of administration is uncomfortable, control of continuous intake of the drug is not ensured and the drug is sometimes discontinued by patients after some time due to the treatment method.
Der Einnahme eines solchen Medikaments als Injektinslösung haften demnach Nachteile an, die es vorliegend zu beseitigen gilt.Accordingly, taking such a drug as an injection solution has disadvantages that need to be eliminated in the present case.
Darstellung der ErfindungPresentation of the invention
Der vorliegenden Erfindung liegt die Aufgabe zugrunde, die vorgenannten Nachteile zu beseitigen und eine Einrichtung zu schaffen, welche eine kontinuierliche und für den Patienten angenehme Abgabe des blutzuckersenkenden Wirkstoffes gewährleistet.The object of the present invention is to eliminate the aforementioned disadvantages and to provide a device which ensures a continuous release of the blood-sugar-lowering active substance which is pleasant for the patient.
Erfindungsgemäß wird die voranstehende Aufgabe gemäß dem Oberbegriff des Anspruchs 1 in Verbindung mit den kennzeichnenden Merkmalen gelöst. Vorteilhafte Ausgestaltungen und Weiterbildungen der erfindungsgemäßen Einrichtung sind in den abhängigen Unteransprüchen angegeben.According to the invention, the above object is achieved according to the preamble of claim 1 in conjunction with the characterizing features. Advantageous refinements and developments of the device according to the invention are specified in the dependent subclaims.
Ausführung der Erfindungimplementation of the invention
Weitere Ziele, Merkmale, Vorteile und Anwendungsmöglichkeiten der erfindungsgemäßen Einrichtung ergeben sich aus der nachfolgenden Beschreibung eines Ausführungsbeispiels.Further goals, features, advantages and possible applications of the device according to the invention result from the following description of an exemplary embodiment.
Die erfindungsgemäße Einrichtung umfasst erfindungsgemäß ein flexibles, klebendes, pharmazeutisches Mittel zum Auflegen auf die Haut, das einen oder mehrere blutzuckersenkende Wirkstoffe enthält, wobei die Einrichtung ausgebildet ist, den enthaltenen blutzuckersenkenden Wirkstoff in kontinuierlicher Weise über die Hautbarriere in den Blutkreislauf abzugeben.According to the invention, the device according to the invention comprises a flexible, adhesive, pharmaceutical agent to be placed on the skin, which contains one or more blood-sugar-lowering active ingredients, the device being designed to continuously release the blood-sugar-lowering active ingredient contained therein via the skin barrier into the bloodstream.
In einer weiteren bevorzugten Ausführungsform der Erfindung ist das Mittel ein Matrix- oder Membranpflaster. Mittels einem solchen Pflaster kann der enthaltene Wirkstoffe kontinuierlich über die Hautbarriere in den Blutkreislauf abgegeben werden und übt ihre Effekte systemisch aus. Die Wirkung tritt dabei zwar mit einer zeitlichen, aber noch kontrollierbaren Verzögerung ein, weshalb sie sich vornehmlich für eine Dauertherapie eignet.In a further preferred embodiment of the invention, the agent is a matrix or membrane patch. By means of such a patch, the active ingredients contained can be released continuously via the skin barrier into the bloodstream and exert their effects systemically. The effect occurs with a temporal but still controllable delay, which is why it is primarily suitable for long-term therapy.
Der blutzuckersenkende Wirkstoff ist vorzugsweise Semaglutid, welches aufgrund seiner blutzuckersenkenden und antidiabetischen Eigenschaften, zur Erhaltungstherapie gegen ein Typ-2-Diabetes bei Patienten eingesetzt werden kann.The blood-sugar-lowering active substance is preferably semaglutide, which, because of its blood-sugar-lowering and antidiabetic properties, can be used for maintenance therapy against type 2 diabetes in patients.
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102022100991.2A DE102022100991A1 (en) | 2022-01-17 | 2022-01-17 | Device for the controlled administration of a blood sugar-lowering agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102022100991.2A DE102022100991A1 (en) | 2022-01-17 | 2022-01-17 | Device for the controlled administration of a blood sugar-lowering agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE102022100991A1 true DE102022100991A1 (en) | 2023-07-20 |
Family
ID=86990602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE102022100991.2A Pending DE102022100991A1 (en) | 2022-01-17 | 2022-01-17 | Device for the controlled administration of a blood sugar-lowering agent |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE102022100991A1 (en) |
-
2022
- 2022-01-17 DE DE102022100991.2A patent/DE102022100991A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2323645B1 (en) | Use of low-dose local anaesthetic or derivatives thereof for therapy of chronic pain, especially migraine | |
| DE202009017772U1 (en) | Combination preparations with cytokine antagonist and corticosteroid | |
| WO2018224559A1 (en) | Microneedle system for applying glucagon-like peptide analogues | |
| EP2319530A1 (en) | Method for treating and/or preventing multiple sclerosis, and use of erythropoietin in the production of a drug for intermittent treatment and/or intermittent prevention of multiple sclerosis | |
| DE102022100991A1 (en) | Device for the controlled administration of a blood sugar-lowering agent | |
| DE69529819T2 (en) | NEW COMBINATION OF A BETABLOCKER WITH A LOCAL ANESTHETIC | |
| DE602004007304T2 (en) | Use of N2O for the treatment of postischemic cerebral cell damage | |
| WO2010072277A1 (en) | Local anesthetic for relieving breast pain | |
| EP1393770B1 (en) | Medical article | |
| DE102021132333A1 (en) | Device for the controlled administration of an antipsychotic agent | |
| DE2444652A1 (en) | MEANS FOR CONTROLLING LOCAL PAIN | |
| EP0910364A1 (en) | Buffered compositions containing a local anaesthetic and used as an anti-inflammatory | |
| DE2658059A1 (en) | AGENTS FOR THE TREATMENT OF DISEASE DISORDERS OF GLUCOSE METABOLISM | |
| DE102020100145B4 (en) | Pre-filled syringe of composition for treating inflammatory joint disease | |
| DE4110422A1 (en) | MEDICINE CONTAINING HUMANESE CORTICOTROPIN RELEASING HORMON (CRH) AND / OR THEIR DERIVATIVES AND / OR GLUCOCORTICOIDS OF NATURAL AND / OR SYNTHETIC PROVENANCE | |
| Cetinkaya et al. | Can adding ephedrine to admixture of propofol & lidocaine overcome propofol associated hemodynamic changes and injection pain | |
| DE1667925A1 (en) | drug | |
| DE102006002793A1 (en) | Liquid pharmaceutical form comprises electrically charged solution having electrical diffusion characteristic, and other usual active substances, where the pharmaceutical form is introduced into blood stream of patient without syringe | |
| DE10319837A1 (en) | Preventing or treating inner ear diseases, e.g. due to ototoxic medicaments, by administration of noble gas selected from argon, xenon, krypton, helium and/or neon | |
| DE2144060C3 (en) | Medicines with an anticonvulsant effect | |
| DE102004059613A1 (en) | Composition and method of topical therapy of atopic dermatitis | |
| DE2057174A1 (en) | Pharmaceutical product, in particular injectable local anesthetic | |
| Bergelt et al. | Onkologische Rehabilitation | |
| DE102006001994A1 (en) | Composition and method, useful e.g. for topical therapy of abdominal irritation and pain-pathology, comprises using a topical plaster system comprising sodium-canal blocker by applying directly over the skin surface of abdominal region | |
| DE3210242A1 (en) | Device for administration of a medicament into the blood stream |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R082 | Change of representative |